KALAMAZOO, Mich., Oct. 12 /PRNewswire-FirstCall/ -- Stryker Corporation disclosed today that the United States Securities and Exchange Commission has made an informal inquiry of the Company regarding possible violations of the Foreign Corrupt Practices Act in connection with the sale of medical devices in certain foreign countries. Stryker is fully cooperating with the U.S. Securities and Exchange Commission regarding this informal investigation.
Stryker Corporation is one of the world’s leading medical technology companies with the most broadly based range of products in orthopaedics and a significant presence in other medical specialties. Stryker works with respected medical professionals to help people lead more active and more satisfying lives. The Company’s products include implants used in joint replacement, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; and endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment. For more information about Stryker, please visit the company web site at www.stryker.com.
CONTACT: Katherine A. Owen, Vice President, Strategy and Investor
Relations of Stryker Corporation, +1-269-385-2600
Web site: http://www.stryker.com//
